Lilly Stock Near A High: What Can Democrats Change?
For questions about this article or underlying research, email help@trefis.com.
Part of our midterms guide. Start here: what the vote really changes for your money.
Betting markets give Democrats about a 94% chance of winning the House on Tuesday, and about three in four of taking the Senate too. President Trump keeps his veto. For drug stocks, the twist is that the toughest pricing moves of the past year came from a Republican White House. The question is what’s left for Congress to do.
| Company | Value | 12-month return | What’s at stake | Exposure to the vote |
|---|---|---|---|---|
| Eli Lilly (LLY) | $1.26T | +65% | Medicare coverage of obesity drugs | Medium |
| Merck (MRK) | $366B | +78% | Medicare negotiation of cancer drugs | Medium |
| Novo Nordisk (NVO) | $180B | −14% | Same as Lilly, with a weaker hand | Medium |
| Pfizer (PFE) | $175B | +33% | First to sign a price deal; tariff relief to 2029 | Low |
The scariest policy for drugmakers is already priced in. The stocks went up anyway.
Pfizer closed at a 52-week high, and Lilly within 1% of one. Lilly’s sales rose 39% last quarter, to $24.4 billion, on its obesity and diabetes drugs. Products, not politics, drove the year.
See more lines: how we ranked them
Exposure is our judgment of how much Tuesday’s outcome can change each company’s revenue, costs or legal risk, given that a Democratic House can investigate, write budgets and block bills, but can’t pass laws past a veto. Values and returns are at the Nov 2 close (Trefis market data). Novo Nordisk’s U.S.-listed shares are down about 17% in 2026. For scale: Johnson & Johnson ($652B, +46%) and AbbVie ($511B, +36%).
What Has The White House Already Done?
Three things. First, price deals. Pfizer signed first, in 2025, and the White House says 26 drugmakers now cover 89% of the branded market. They cut prices for Medicaid and cash buyers and promise the lowest rich-country price on new drugs.
Second, tariffs. Signers are exempt from a 100% tariff on patented drugs through January 2029. That’s past the next presidential election, and no House vote changes it.
Third, obesity drugs. Under the Lilly and Novo deals, Medicare pays $245 a month for Wegovy and Zepbound, and patients pay $50. A pilot started July 1 for patients with severe obesity, or obesity plus a related illness.
And Medicare Negotiation?
It runs on its own. The 2022 law that set it up was a Democratic law, and it still stands. For the first time, the 2028 round includes drugs given in doctors’ offices, like Botox. Medicare must publish those prices by Nov. 30, 2026, four weeks after the vote. Keytruda, Merck’s biggest seller, isn’t on that list, but Lilly’s Trulicity is.
So What Can A Democratic House Change?
Hearings on the deals. Most terms are private. Democrats will ask whether the cuts are real. One report found the price site listed fewer than 12% of the signers’ brand drugs in July.
The obesity pilot. It’s a pilot, not a law. It ends in December 2027, and a lasting benefit needs Congress. That’s Lilly’s and Novo’s biggest political upside, not risk.
The 2027 debt limit. Democrats want health-care money back. More drugs in Medicare negotiation, sooner, is a classic way to pay for it. That’s the one real threat, and it’s a 2027 story.
What Could Go Wrong?
Both parties like cutting drug prices. A populist White House and a Democratic House could agree to write the deals into law, which would make them permanent. And the obesity race could turn: Lilly is priced for leadership, and Novo shows how fast a leader can slip.
Most exposed: Merck and Novo Nordisk. Least: Pfizer. The price deals, the tariff relief and Medicare negotiation were decided before Tuesday. Watch Nov. 30 for the 2028 Medicare prices and the 2027 debt limit for new cuts. Lilly may even gain if Congress makes obesity coverage permanent.
For the big picture, see Will The Midterms Move Your Stocks? Health care’s likely winners: 3 stocks that could pop if Democrats win.
How Much Of Your Portfolio Rides On One Drug?
Elections change the odds, not your plan. If you have $1 million or more invested, see what Tuesday means for your portfolio in a free 15-minute call with a Trefis partner – an expert financial advisor.
Spot an error or want more like this? Tell us in 10 seconds.